Contrasting Effects Of Chronic, Systemic Treatment With mTOR Inhibitors Rapamycin And Metformin On Adult Neural Progenitors In Mice
Research Summary
A mouse and cell-culture study asking whether two different ways of inhibiting mTOR – rapamycin directly, or metformin indirectly through AMPK – have the same effect on adult neural stem cells in the brain.
Who Or What Was Studied?
Adult male C57BL/6J mice, three months old at the start of treatment, given daily intraperitoneal injections for about nine weeks of rapamycin at 75 µg/kg (low dose) or 2.5 mg/kg (high dose, matched to a lifespan-extending dose), metformin at 200 mg/kg, or PBS as control, with at least five mice per group. Also neural stem cells isolated from the subventricular zone of postnatal day 30 mice and grown in culture as neurospheres or adherent monolayers.
What Did The Research Show?
- Both rapamycin doses and metformin reduced phosphorylation of ribosomal protein S6 in the cortex, confirming that mTOR signalling was inhibited in the brain by all three regimens.
- In the subventricular zone, the number of BrdU-positive cells was significantly lower in both rapamycin groups, and Ki67 staining gave the same result; metformin did not significantly change BrdU incorporation.
- In the dentate gyrus the rapamycin-treated mice also had fewer BrdU-positive cells than control or metformin-treated mice (p < 0.01), and chronic rapamycin reduced the number of doublecortin-positive neuroblasts in the subventricular zone.
- In cultured neural stem cells, 200 nM rapamycin inhibited BrdU incorporation by about 23% and raised the proportion of cells in G1 phase from 78.7% to 85.7%. Metformin at 500 µM did neither, and neither drug increased apoptosis.
- Rapamycin-treated cultures failed to express the neuronal marker Tuj1 and retained the progenitor marker Nestin under differentiation conditions, indicating reduced neuronal differentiation in vitro.
Limitations And Interpretation
- Animal and cell-culture data only: the drug was given by daily intraperitoneal injection, which is not how people take rapamycin.
- No behavioural, learning or memory outcomes were measured, so the functional consequence of fewer new neurons was not established.
- The reason rapamycin and metformin differ is not identified; the authors suggest mTORC2 inhibition or different feedback pathways as possible explanations.
- The high rapamycin dose also caused weight loss in the mice, a confounder that the paper does not resolve.
Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.